Clinical Trial Update: Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Acalabrutinib is being evaluated in Phase 1/2 studies in Chinese adults with relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukemia (plus …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)

Snippet

Sponsor: AstraZeneca | Conditions: Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-03-20